EP Patent

EP3346996A1 — Oral pharmaceutical dosage forms of budesonide

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2018-07-18 · 8y expired

What this patent protects

The present invention relates to a sustained release pharmaceutical dosage form for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease. Said dosage form comprises (a) an inert core, (b) a first layer composed of sugar and an insoluble …

USPTO Abstract

The present invention relates to a sustained release pharmaceutical dosage form for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease. Said dosage form comprises (a) an inert core, (b) a first layer composed of sugar and an insoluble polymer (e.g. ethyl cellulose) in a ratio greater than 3:1 and (c) a second delayed film coating, which is preferably an enteric coating.

Drugs covered by this patent

Patent Metadata

Patent number
EP3346996A1
Jurisdiction
EP
Classification
—
Expires
2018-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.